Artificial Blood Vessels Market Size, Share and Trends 2024 to 2034

Artificial Blood Vessels Market Size and Forecast 2024 to 2034

The global artificial blood vessels market size is projected to be worth around USD 3.75 billion by 2034 from USD 2.23 billion in 2024, at a CAGR of 5.33% from 2024 to 2034. The demand for the artificial blood vessels market is primarily being boosted by the rising prevalence of various cardiovascular diseases coupled with a rapidly growing geriatric population.

Artificial Blood Vessels Market Key Takeaways

• North America dominated the artificial blood vessels market in 2023.
• Asia Pacific is expected to show the fastest growth in the market over the forecast period
• By polymer type, the polyethylene terephthalate segment dominated the market in 2023.
• By polymer type, the polydioxanone segment is expected to show notable growth in the market over the forecast period.
• By application, the aortic disease segment led the market in 2023.
• By application, the hemodialysis segment is expected to show notable growth in the market over the forecast period.
• By end-users, the hospital's segment led the market in 2023
• By end-users, the ambulatory surgical centers segment is expected to experience the fastest growth in the market during the forecast period.

Market Overview

Artificial blood vessels, or synthetic tubes, are employed to restore blood circulation. These vessels are crafted from biosynthetic materials such as polydioxanone and polyethylene terephthalate and are known for their excellent conductivity, high oxygen permeability, and strong chemical and water resistance. Hemoglobin-based oxygen carriers are commonly used as artificial blood vessels to deliver oxygen molecules to the heart vessels from the bloodstream by aiding in the restoration of normal heart function.

Recently, silk was introduced into the production of these artificial vessels. Cardiovascular diseases can involve various pathophysiological mechanisms like stenosis, occlusion, or severe dysfunction of blood vessels. Conditions affecting the aorta include abdominal aortic aneurysm, aortic coarctation, and chronic hemodialysis access, among others.

Artificial Blood Vessels Market Growth Factors

• Technological breakthroughs in biomaterials are anticipated to fuel the artificial blood vessels market growth.
• Rising investment in infrastructure development along with healthcare facilities can further propel the artificial blood vessels market growth.
• Strategic partnerships among key market players can help in the artificial blood vessels market expansion.
• The development of novel artificial blood vessels can boost market growth during the forecast period.

How will AI help the artificial blood vessels market?

AI can analyze vast datasets to predict the performance of artificial blood vessels under different physiological conditions. This helps in designing more effective and durable vessels by simulating how they will behave in the human body before actual physical testing. AI algorithms can identify the most suitable materials for artificial blood vessels by analyzing their properties and predicting their interaction with human tissues. This accelerates the development of biocompatible materials that minimize the risk of rejection and complications.

AI can assist in creating personalized artificial blood vessels tailored to individual patients. By analyzing patient-specific data, such as imaging scans and physiological parameters, AI can help design vessels that match the exact size, shape, and mechanical properties needed for each patient.

Market Scope

Market Dynamics

Driver

Rise in aortic diseases

The artificial blood vessels market is set to expand due to the increasing incidence of aortic diseases globally. As the largest blood vessel in the body, the aorta is vulnerable to various disorders, with aortic aneurysms being the most frequently reported condition. Additionally, Other factors impacting the aortae include atherosclerosis, genetic disorders, hypertension, connective tissue diseases, and physical injury. The rising prevalence of these conditions is expected to drive the growth of the market for artificial blood vessels.

• In October 2023, Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced data from its On-X Aortic Heart Valve Low INR post-market study presented in a Late-Breaking Science session at the 37th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Vienna, Austria. Real-world interim results for all patients confirm that the On-X Aortic Valve remains safe and effective with low-dose warfarin.

Restraint

Limited long-term data

There may be a shortage of extensive data regarding the durability and efficacy of artificial blood vessels over extended periods. This absence of thorough information can lead to apprehensions among both healthcare providers and patients about the reliability and lifespan of these devices. Moreover, patients might choose alternative treatments, such as conventional vascular surgeries or medications, in place of artificial blood vessels. This competition from other therapeutic approaches can influence the demand within the artificial blood vessels market.

Opportunity

TEVGs technic

A major trend in the artificial blood vessels market is the development of next-generation tissue engineered vascular grafts (TEVGs). Cardiovascular diseases (CVDs), which include conditions like stenosis or blood vessel occlusion, are a leading cause of death worldwide. These conditions often require vascular interventions such as minimally invasive direct coronary artery bypass (MEDICAL) or coronary artery bypass grafting (CABG). Furthermore, conventional surgical methods utilize autologous vessels, such as saphenous veins and internal thoracic arteries, or prosthetic grafts like polyester vascular grafts and hybrid vascular grafts. This innovative technique can create market opportunities for the future.

• In January 2022, an article published in Medical Press says that tissue-engineered vascular grafts” can advance the surgical management of infants and children who require congenital heart surgery by creating functional vascular conduits with growth capacity. Congenital heart surgery is aimed at correcting birth defects and requires the development of artificial blood vessels known as vascular grafts.

Polymer Type Insights

The polyethylene terephthalate segment dominated the artificial blood vessels market in 2023. These biostable polymers are currently the standard biomaterials used for vascular grafts in various clinical settings, including polyethylene terephthalate (PET). PET, which is widely utilized in textile manufacturing and as packaging for food and beverages, accounts for approximately 10% of the synthetic plastic polymers produced globally. Although many enzymes capable of degrading PETs have been identified, their activity is relatively low. The most promising enzyme-producing species for PET degradation discovered to date is Ideonella sakaiensis.

The polydioxanone segment is expected to show notable growth in the artificial blood vessels market over the forecast period. Introduced as the first mono-filament synthetic absorbable suture, polydioxanone offers several advantages. Its monofilament design facilitates smoother passage through tissues, reduces tissue reactivity, and lowers the risk of wound infection. However, this design also results in reduced handling and knot strength due to its lower coefficient of friction. Compared to Polyglactin 910 or polyglycolic acid, polydioxanone exhibits lower initial tensile strength.

• In September 2022, PDO MAX, Inc., a woman-owned aesthetics medical device company based in the United States, launched the first polydioxanone (PDO) topical serum skin booster called PDO AfterGlo.This new PDO serum improves the appearance of fine lines, wrinkles, and dark circles while improving skin complexion.

Application Insights

The aortic disease segment led the artificial blood vessels market in 2023. The increasing prevalence of numerous medical conditions and diseases that can damage the aorta and pose serious health risks to patients is a major concern. Aortic dissection is characterized by a rupture in the intima, the aorta's innermost layer. However, this rupture allows blood to enter the media, forming a dissection flap filled with blood. This flap can extend in either direction along the aortic long axis, either forward (antegrade) or backward (retrograde).

The hemodialysis segment is expected to show notable growth in the artificial blood vessels market over the forecast period. Hemodialysis is a procedure that purifies blood using a dialysis machine and a dialyzer, often referred to as an artificial kidney. The effectiveness of dialysis can be influenced by several factors, including the type of vascular access, the kind of filter used, the device employed, and the dosage and route of erythropoietin-stimulating agents (ESA). Hemodialysis effectively clears small-molecular-weight toxins and corrects imbalances in electrolytes and acid-base levels.

• In June 2022, Quanta Dialysis Technologies raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta also used the money to launch its technology in the UK later that same year and also applied for FDA approval.

End-use Insights

The hospital's segment led the artificial blood vessels market in 2023. This can be attributed to the rise in heart surgery in hospitals.  Technological advancements can greatly enhance hospital development by increasing efficiency, lowering expenses, and improving patient outcomes. Important technological approaches include electronic health records (EHR), which include upgrading or adopting EHR systems to improve data management and patient care coordination.

The ambulatory surgical centers segment is expected to experience the fastest growth in the artificial blood vessels market during the forecast period. These centers are intended to assess and address conditions that are not critical enough to need hospital emergency department care but still require treatment outside of typical physician office hours or before an available physician appointment. Ambulatory surgery centers (ASCs) offer cost-efficient services in a more relaxed setting compared to many hospitals, which can often be more stressful. These factors can lead to segment growth.

Regional Insights

North America dominated the artificial blood vessels market in 2023. The rising incidence of aortic diseases in the region is expected to drive market growth. In North America, the U.S. is anticipated to hold the largest market share due to its advanced healthcare infrastructure and technological innovations. Additionally, the increasing number of smokers, who are at a higher risk for aortic conditions, contributes to this trend.

This growing burden of aortic diseases is likely to enhance the demand for artificial blood vessels. The well-established healthcare system in the United States fosters research and development, attracting global players to enter the market. The presence of numerous international companies in the U.S. and Canada is helping meet the high and rising demand for these products. Hence, the artificial blood vessels market is projected to continue expanding in the region.

Asia Pacific is expected to show the fastest growth in the artificial blood vessels market over the forecast period. This is due to the rise in awareness, which has led to the emergence of smaller players in the region, contributing to market growth. Companies are leveraging strategies such as mergers and acquisitions, expansions, investments, new service launches, and collaborations to explore new market opportunities. By entering new geographies through these strategies, they aim to gain a competitive edge through combined synergies. Furthermore, companies from the Asia-Pacific region will drive substantial growth in the global artificial blood vessels market throughout the forecast period.

• In November 2022, Jiangsu Bioda Life Science Co. Ltd.’s artificial blood vessel gained class III medical device approval from China’s NMPA, marking the first domestic artificial blood vessel to get such approval. Nantong, China-based Bioda’s vessel is used for aortic coarctation and aneurysms.

Artificial Blood Vessels Market Companies

• Braun Melsungen
• Becton
• Dickinson and Company
• Cook Medical Incorporated
• Medtronic
• LeMaitre Vascular Inc.
• Terumo Medical Corporation
• W. L. Gore and Associates
• Jotec GmbH
• Humacyte Inc.
• Techshot Inc.

Recent Developments

• In February 2023, Terumo Corporation launched its new hydrophilic polymer-covered vascular guidewire, the Terumo Guidewire Apex. The guidewire is designed to provide advanced trackability and flexibility, making it simpler to navigate through tortuous vessels.
• In March 2023, Abbott Vascular launched its new nitinol vascular guidewire, the Abbott Vascular Guidewire Maestro. The guidewire is designed to be more flexible and steerable than traditional nitinol guidewires, making it less complicated to apply in complicated processes.
• In October 2022, VentureMed Group Inc. announced the first patient treated with The FLEX Vessel Prep™ System AV Focused 75cm Product.

Segments Covered in the Report

By Polymer Type

• Polydioxanone
• Elastomer
• Polyethylene Terephthalate
• Others

By End-users

• Hospitals
• Cardiac Catheterization Laboratories
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Application

• Aortic Disease
• Peripheral Artery Disease
• Hemodialysis

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa